BeOne-BGB-11417-304
What is the Purpose of this Study?
You will be randomly assigned to one of two study arms:
• Arm A: Sonrotoclax + Zanubrutinib
• Arm B: Venetoclax + Acalabrutinib
The study includes Screening (up to 35 days), Study Treatment, and Follow‑up. Screening involves exams, blood tests, heart tests, and imaging. Treatment includes oral medications with ramp‑up dosing schedules and regular monitoring.
Chronic Lymphocytic Leukemia (CLL) in adults who have not received prior treatment
Who Can Participate in the Study?
People can join this study if they are 18 years or older and have a confirmed diagnosis of CLL. They must have organs that are working well and complete the required health checks before joining. If they can become pregnant, they must have a negative pregnancy test and agree to use birth control during the study.
What is Involved?
This study is comparing two pairs of cancer medicines to see which one works better for treating CLL. One pair is sonrotoclax and zanubrutinib. The other pair is venetoclax and acalabrutinib. The study is open label, which means you and your doctor will know which medicines you are getting.
Study Details
